Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Padilha EC, Wang J, Kerns E, Lee A, Huang W, Jiang JK, McKew J, Mutlib A, Peccinini RG, Yu PB, Sanderson P, Xu X.

Front Pharmacol. 2019 Apr 24;10:234. doi: 10.3389/fphar.2019.00234. eCollection 2019.

2.

Letter by Morrell et al Regarding Article, "Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension".

Morrell NW, Upton PD, Li W, Yu PB.

Circ Res. 2019 Apr 26;124(9):e81. doi: 10.1161/CIRCRESAHA.119.314962. No abstract available.

PMID:
31021722
3.

Isolating pulmonary microvascular endothelial cells ex vivo: Implications for pulmonary arterial hypertension, and a caution on the use of commercial biomaterials.

Wertheim BM, Lin YD, Zhang YY, Samokhin AO, Alba GA, Arons E, Yu PB, Maron BA.

PLoS One. 2019 Feb 27;14(2):e0211909. doi: 10.1371/journal.pone.0211909. eCollection 2019.

4.

In Search of the Second Hit in Pulmonary Arterial Hypertension.

Yang P, Yu PB.

Circ Res. 2019 Jan 4;124(1):6-8. doi: 10.1161/CIRCRESAHA.118.314270. No abstract available.

PMID:
30605416
5.

Pharmacologic Strategies for Assaying BMP Signaling Function.

Dinter T, Bocobo GA, Yu PB.

Methods Mol Biol. 2019;1891:221-233. doi: 10.1007/978-1-4939-8904-1_16.

PMID:
30414136
6.

[A clinical investigation of plaque control efficacy and safety of Sonicare toothbrush in children].

Zhao SM, Chen H, Yu PB, Wang J.

Shanghai Kou Qiang Yi Xue. 2018 Jun;27(3):313-317. Chinese.

PMID:
30411132
7.

Room With a View.

Yung LM, Yu PB.

Circ Cardiovasc Imaging. 2018 Aug;11(8):e008148. doi: 10.1161/CIRCIMAGING.118.008148. No abstract available.

PMID:
30354505
8.

Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.

Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage SD, Dinter T, Bocobo GA, Tumelty KE, Faugno AJ, Troncone L, McNeil ME, Huang X, Coser KR, Lai CSC, Upton PD, Goumans MJ, Zamanian RT, Elliott CG, Lee A, Zheng W, Berasi SP, Huard C, Morrell NW, Chung RT, Channick RW, Roberts KE, Yu PB.

Am J Respir Crit Care Med. 2019 Apr 1;199(7):891-902. doi: 10.1164/rccm.201807-1236OC.

PMID:
30312106
9.

Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.

Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.

Bioorg Med Chem Lett. 2018 Nov 1;28(20):3356-3362. doi: 10.1016/j.bmcl.2018.09.006. Epub 2018 Sep 6.

PMID:
30227946
10.

CYP3A4*1B Polymorphism and Cancer Risk: A Meta-Analysis Based on 55 Case-control Studies.

Zheng Y, Xu Y, Zhou BY, Sun L, Yu PB, Zhang L, Xu J, Wang JJ.

Ann Clin Lab Sci. 2018 Jul;48(4):538-545.

PMID:
30143500
11.

Finding the Target: In Silico and Genetic Screening for Mechanistically Novel Drugs in Pulmonary Arterial Hypertension.

Graham BB, Yu PB.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):9-11. doi: 10.1164/rccm.201808-1427ED. No abstract available.

PMID:
30130137
12.

NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaap7294. doi: 10.1126/scitranslmed.aap7294.

13.

Career Development of Young Physician-Scientists in the Cardiovascular Sciences: Perspective and Advice From the Early Career Committee of the Cardiopulmonary, Critical Care, and Resuscitation Council of the American Heart Association.

Agarwal S, Spiekerkoetter E, Austin ED, de Jesus Perez V, Dezfulian C, Maron BA, Ryan JJ, Starks MA, Yu PB, Bonnet S, Perman SM.

Circ Res. 2018 May 11;122(10):1330-1333. doi: 10.1161/CIRCRESAHA.118.312999. No abstract available.

14.

Update in Pulmonary Vascular Disease 2016 and 2017.

Brittain EL, Thennapan T, Maron BA, Chan SY, Austin ED, Spiekerkoetter E, Bogaard HJ, Guignabert C, Paulin R, Machado RF, Yu PB.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):13-23. doi: 10.1164/rccm.201801-0062UP. No abstract available.

PMID:
29533671
15.

Correction for Bagarova et al., "Constitutively Active ALK2 Receptor Mutants Require Type II Receptor Cooperation".

Bagarova J, Vonner AJ, Armstrong KA, Börgermann J, Lai CSC, Deng DY, Beppu H, Alfano I, Filippakopoulos P, Morrell NW, Bullock AN, Knaus P, Mishina Y, Yu PB.

Mol Cell Biol. 2017 Sep 12;37(19). pii: e00284-17. doi: 10.1128/MCB.00284-17. Print 2017 Oct 1. No abstract available.

16.

Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification.

Agarwal S, Loder SJ, Breuler C, Li J, Cholok D, Brownley C, Peterson J, Hsieh HH, Drake J, Ranganathan K, Niknafs YS, Xiao W, Li S, Kumar R, Tompkins R, Longaker MT, Davis TA, Yu PB, Mishina Y, Levi B.

Mol Ther. 2017 Aug 2;25(8):1974-1987. doi: 10.1016/j.ymthe.2017.01.008. Epub 2017 Jul 15.

17.

Persistence of immune responses to vaccine against haemorrhagic fever with renal syndrome in healthy adults aged 16-60 years: results from an open-label2-year follow-up study.

Zheng Y, Zhou BY, Wei J, Xu Y, Dong JH, Guan LY, Ma P, Yu PB, Wang JJ.

Infect Dis (Lond). 2018 Jan;50(1):21-26. doi: 10.1080/23744235.2017.1353704. Epub 2017 Jul 13.

PMID:
28703073
18.

The traumatic bone: trauma-induced heterotopic ossification.

Dey D, Wheatley BM, Cholok D, Agarwal S, Yu PB, Levi B, Davis TA.

Transl Res. 2017 Aug;186:95-111. doi: 10.1016/j.trsl.2017.06.004. Epub 2017 Jun 15. Review.

PMID:
28668522
19.

The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.

Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN.

Bone. 2018 Apr;109:210-217. doi: 10.1016/j.bone.2017.06.011. Epub 2017 Jun 16. Review.

20.

Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension.

DuBrock HM, Rodriguez-Lopez JM, LeVarge BL, Curry MP, VanderLaan PA, Zsengeller ZK, Pernicone E, Preston IR, Yu PB, Nikolic I, Xu D, Thadhani RI, Channick RN, Ananth Karumanchi S.

Pulm Circ. 2016 Dec;6(4):498-507. doi: 10.1086/688489.

21.

Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification.

Dey D, Bagarova J, Hatsell SJ, Armstrong KA, Huang L, Ermann J, Vonner AJ, Shen Y, Mohedas AH, Lee A, Eekhoff EM, van Schie A, Demay MB, Keller C, Wagers AJ, Economides AN, Yu PB.

Sci Transl Med. 2016 Nov 23;8(366):366ra163.

22.

A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension.

Yung LM, Nikolic I, Paskin-Flerlage SD, Pearsall RS, Kumar R, Yu PB.

Am J Respir Crit Care Med. 2016 Nov 1;194(9):1140-1151.

23.

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation.

O'Rourke C, Shelton G, Hutcheson JD, Burke MF, Martyn T, Thayer TE, Shakartzi HR, Buswell MD, Tainsh RE, Yu B, Bagchi A, Rhee DK, Wu C, Derwall M, Buys ES, Yu PB, Bloch KD, Aikawa E, Bloch DB, Malhotra R.

J Vis Exp. 2016 May 31;(111). doi: 10.3791/54017.

24.

The Role of Bone Marrow-derived Cells in Pulmonary Arterial Hypertension. What Lies Beneath?

Nikolic I, Yu PB.

Am J Respir Crit Care Med. 2016 Apr 15;193(8):822-4. doi: 10.1164/rccm.201511-2293ED. No abstract available.

25.

Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension.

Aghamohammadzadeh R, Zhang YY, Stephens TE, Arons E, Zaman P, Polach KJ, Matar M, Yung LM, Yu PB, Bowman FP, Opotowsky AR, Waxman AB, Loscalzo J, Leopold JA, Maron BA.

FASEB J. 2016 Jul;30(7):2511-27. doi: 10.1096/fj.201500042. Epub 2016 Mar 22.

26.

Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage.

Szulcek R, Happé CM, Rol N, Fontijn RD, Dickhoff C, Hartemink KJ, Grünberg K, Tu L, Timens W, Nossent GD, Paul MA, Leyen TA, Horrevoets AJ, de Man FS, Guignabert C, Yu PB, Vonk-Noordegraaf A, van Nieuw Amerongen GP, Bogaard HJ.

Am J Respir Crit Care Med. 2016 Jun 15;193(12):1410-20. doi: 10.1164/rccm.201506-1231OC.

PMID:
26760925
27.

Long-term persistence of anti-hantavirus antibodies in sera of patients undergoing hemorrhagic fever with renal syndrome and subjects vaccinated against the disease.

Zheng Y, Wei J, Zhou BY, Xu Y, Dong JH, Guan LY, Ma P, Yu PB, Wang JJ.

Infect Dis (Lond). 2016 Apr;48(4):262-266. doi: 10.3109/23744235.2015.1121289. Epub 2015 Dec 11.

PMID:
26654580
28.

Contributions of muscle-resident progenitor cells to homeostasis and disease.

Dey D, Goldhamer DJ, Yu PB.

Curr Mol Biol Rep. 2015 Dec;1(4):175-188. doi: 10.1007/s40610-015-0025-z. Epub 2015 Oct 10.

29.

Brief Report: Coordinated Modulation of Circulating miR-21 in HIV, HIV-Associated Pulmonary Arterial Hypertension, and HIV/Hepatitis C Virus Coinfection.

Parikh VN, Park J, Nikolic I, Channick R, Yu PB, De Marco T, Hsue PY, Chan SY.

J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):236-41. doi: 10.1097/QAI.0000000000000741.

30.

Targeting BMP signalling in cardiovascular disease and anaemia.

Morrell NW, Bloch DB, ten Dijke P, Goumans MJ, Hata A, Smith J, Yu PB, Bloch KD.

Nat Rev Cardiol. 2016 Feb;13(2):106-20. doi: 10.1038/nrcardio.2015.156. Epub 2015 Oct 13. Review.

31.

Excess placental secreted frizzled-related protein 1 in maternal smokers impairs fetal growth.

Wang A, Zsengellér ZK, Hecht JL, Buccafusca R, Burke SD, Rajakumar A, Weingart E, Yu PB, Salahuddin S, Karumanchi SA.

J Clin Invest. 2015 Nov 2;125(11):4021-5. doi: 10.1172/JCI80457. Epub 2015 Sep 28.

32.

Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells.

Yung LM, Sánchez-Duffhues G, Ten Dijke P, Yu PB.

Cardiovasc Res. 2015 Nov 1;108(2):278-87. doi: 10.1093/cvr/cvv221. Epub 2015 Sep 25.

33.

ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Hatsell SJ, Idone V, Wolken DM, Huang L, Kim HJ, Wang L, Wen X, Nannuru KC, Jimenez J, Xie L, Das N, Makhoul G, Chernomorsky R, D'Ambrosio D, Corpina RA, Schoenherr CJ, Feeley K, Yu PB, Yancopoulos GD, Murphy AJ, Economides AN.

Sci Transl Med. 2015 Sep 2;7(303):303ra137. doi: 10.1126/scitranslmed.aac4358.

34.

Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.

Long L, Ormiston ML, Yang X, Southwood M, Gräf S, Machado RD, Mueller M, Kinzel B, Yung LM, Wilkinson JM, Moore SD, Drake KM, Aldred MA, Yu PB, Upton PD, Morrell NW.

Nat Med. 2015 Jul;21(7):777-85. doi: 10.1038/nm.3877. Epub 2015 Jun 15.

35.

Elafin in pulmonary arterial hypertension. Beyond targeting elastases.

Chun HJ, Yu PB.

Am J Respir Crit Care Med. 2015 Jun 1;191(11):1217-9. doi: 10.1164/rccm.201504-0686ED. No abstract available.

36.

Changes in rodent abundance and weather conditions potentially drive hemorrhagic fever with renal syndrome outbreaks in Xi'an, China, 2005-2012.

Tian HY, Yu PB, Luis AD, Bi P, Cazelles B, Laine M, Huang SQ, Ma CF, Zhou S, Wei J, Li S, Lu XL, Qu JH, Dong JH, Tong SL, Wang JJ, Grenfell B, Xu B.

PLoS Negl Trop Dis. 2015 Mar 30;9(3):e0003530. doi: 10.1371/journal.pntd.0003530. eCollection 2015 Mar.

37.

The first human infection with severe fever with thrombocytopenia syndrome virus in Shaanxi Province, China.

Wei J, Li S, Dong JH, Tian H, Chowell G, Tian HY, Lv W, Han ZQ, Xu B, Yu PB, Wang JJ.

Int J Infect Dis. 2015 Jun;35:37-9. doi: 10.1016/j.ijid.2015.02.014. Epub 2015 Feb 24.

38.

Inhibition of bone morphogenetic protein signal transduction prevents the medial vascular calcification associated with matrix Gla protein deficiency.

Malhotra R, Burke MF, Martyn T, Shakartzi HR, Thayer TE, O'Rourke C, Li P, Derwall M, Spagnolli E, Kolodziej SA, Hoeft K, Mayeur C, Jiramongkolchai P, Kumar R, Buys ES, Yu PB, Bloch KD, Bloch DB.

PLoS One. 2015 Jan 20;10(1):e0117098. doi: 10.1371/journal.pone.0117098. eCollection 2015.

39.

Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation.

Mayeur C, Kolodziej SA, Wang A, Xu X, Lee A, Yu PB, Shen J, Bloch KD, Bloch DB.

Haematologica. 2015 Feb;100(2):e68-71. doi: 10.3324/haematol.2014.111484. Epub 2014 Oct 17. No abstract available.

40.

Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration.

Tsugawa D, Oya Y, Masuzaki R, Ray K, Engers DW, Dib M, Do N, Kuramitsu K, Ho K, Frist A, Yu PB, Bloch KD, Lindsley CW, Hopkins CR, Hong CC, Karp SJ.

J Pharmacol Exp Ther. 2014 Dec;351(3):549-58. doi: 10.1124/jpet.114.216903. Epub 2014 Sep 30.

41.

Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.

Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB.

J Med Chem. 2014 Oct 9;57(19):7900-15. doi: 10.1021/jm501177w. Epub 2014 Sep 4.

42.

C-terminal domain (CTD) small phosphatase-like 2 modulates the canonical bone morphogenetic protein (BMP) signaling and mesenchymal differentiation via Smad dephosphorylation.

Zhao Y, Xiao M, Sun B, Zhang Z, Shen T, Duan X, Yu PB, Feng XH, Lin X.

J Biol Chem. 2014 Sep 19;289(38):26441-50. doi: 10.1074/jbc.M114.568964. Epub 2014 Aug 6.

43.

HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression.

Wu XG, Wang Y, Wu Q, Cheng WH, Liu W, Zhao Y, Mayeur C, Schmidt PJ, Yu PB, Wang F, Xia Y.

Blood. 2014 Aug 21;124(8):1335-43. doi: 10.1182/blood-2014-01-552281. Epub 2014 Jun 5.

44.

Hantavirus infection in rodents and haemorrhagic fever with renal syndrome in Shaanxi province, China, 1984-2012.

Yu PB, Tian HY, Ma CF, Ma CA, Wei J, Lu XL, Wang Z, Zhou S, Li S, Dong JH, Xu JR, Xu B, Wang JJ.

Epidemiol Infect. 2015 Jan;143(2):405-11. doi: 10.1017/S0950268814001009. Epub 2014 May 1.

PMID:
24787374
45.

The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6.

Mayeur C, Lohmeyer LK, Leyton P, Kao SM, Pappas AE, Kolodziej SA, Spagnolli E, Yu B, Galdos RL, Yu PB, Peterson RT, Bloch DB, Bloch KD, Steinbicker AU.

Blood. 2014 Apr 3;123(14):2261-8. doi: 10.1182/blood-2013-02-480095. Epub 2014 Feb 5.

46.

[Genetic characterization of human parainfluenza virus 3 circulating in Gansu and Shaanxi Provinces from 2009 to 2011].

Zhang P, Ji YX, Xu ST, Yu DS, Yu PB, Zhang H, Xu J, Cui AL, Wei HL, Xu WB.

Bing Du Xue Bao. 2013 Sep;29(5):509-14. Chinese.

PMID:
24386839
47.

Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension.

Malhotra R, Paskin-Flerlage S, Zamanian RT, Zimmerman P, Schmidt JW, Deng DY, Southwood M, Spencer R, Lai CS, Parker W, Channick RN, Morrell NW, Elliott CG, Yu PB.

Pulm Circ. 2013 Apr;3(2):369-80. doi: 10.4103/2045-8932.110445.

48.

[Comparison of direct immune-fluorescent assay and real-time quantitative PCR in detecting the Hantavirus].

Yu PB, Li S, Wei J, Ma CA, Lu XL, DU SQ, Guan LY, Zheng Y, Dong JH, Ma CF, Wang JJ.

Zhonghua Yu Fang Yi Xue Za Zhi. 2013 Apr;47(4):367-70. Chinese.

PMID:
23928646
49.

[Analysis the viral etiology of fever and respiratory tract infection syndrome in Shaanxi province].

Shi J, Yu PB, Zhang Y, Cui AL, Xu J, Huang GH, Shi W, Mao NY, Xu WB, Wang JJ, Kong XH.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013 Feb;27(1):8-10. Chinese.

PMID:
23855118
50.

A new class of small molecule inhibitor of BMP signaling.

Sanvitale CE, Kerr G, Chaikuad A, Ramel MC, Mohedas AH, Reichert S, Wang Y, Triffitt JT, Cuny GD, Yu PB, Hill CS, Bullock AN.

PLoS One. 2013 Apr 30;8(4):e62721. doi: 10.1371/journal.pone.0062721. Print 2013.

Supplemental Content

Support Center